Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + Budigalimab + Chemotherapy vs Pembrolizumab + Chemotherapy in Untreated Metastatic Non-Squamous NSCLC
NCT06236438Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Primary completion
- Oct 2031
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of livmoniplimab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Best Overall Response at 21 months and Overall Survival at 55 months. Started Apr 2024; status: active, not recruiting.
02
Drugs
livmoniplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06236438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236438.